logo
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Business Wire15-07-2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, has earned two prestigious workplace honors in 2025, reinforcing its commitment to employee well-being and a strong, values-driven culture. For the third consecutive year, Vistagen received Mental Health America's Platinum Bell Seal for Workplace Mental Health, their highest distinction for mental health standards in the workplace. The company has also been certified as a Great Place to Work ® for the second year in a row.
"These recognitions are an independent and meaningful reflection of our ongoing efforts to foster a workplace where our team feels supported, valued, and inspired,' said Trisha Fitzmaurice, Senior Vice President of Human Resources at Vistagen. 'Internally, they affirm that our people-first approach is impactful. Externally, they show our commitment to setting a high standard for prioritizing mental health and workplace culture across the industry.'
The Platinum Bell Seal is the highest recognition awarded by Mental Health America, the nation's leading nonprofit dedicated to promoting mental well-being. Vistagen underwent a rigorous evaluation of its policies and practices in four areas: workplace culture, benefits, compliance, and wellness programs. According to Mental Health America, only two in five employers who were assessed met the standards for Bell Seal certification, and achieving a platinum designation – awarded only to those scoring between 92% and 100% – reflects the highest standards of workplace mental health support and leadership.
The Great Place to Work ® Certification™ is based on employee feedback about their experiences working at Vistagen. According to Great Place to Work ®, employees at certified workplaces are 93% more likely to look forward to coming to work and are twice as likely to feel that they are paid fairly, earn a fair share of the company's profits, and have a fair chance at promotion.
About Vistagen
Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved.
Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at www.Vistagen.com.
Forward-looking Statements
This press release contains certain forward-looking statements made by Vistagen within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as 'may,' 'could,' 'expect,' 'project,' 'outlook,' 'strategy,' 'intend,' 'plan,' 'seek,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'strive,' 'goal,' 'continue,' 'likely,' 'will,' 'would' and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. These uncertainties, risks, and other matters are more fully discussed in the section entitled 'Risk Factors' in filings Vistagen makes with the U.S. Securities and Exchange Commission (SEC) from time to time. Vistagen's SEC filings are available on the SEC's website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen's views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Campus Expansion Marks Dr. Vince Clinical Research's Investment in People, Infrastructure and Innovation
Campus Expansion Marks Dr. Vince Clinical Research's Investment in People, Infrastructure and Innovation

Yahoo

time25 minutes ago

  • Yahoo

Campus Expansion Marks Dr. Vince Clinical Research's Investment in People, Infrastructure and Innovation

New administration building opens, reinforcing DVCR's commitment to operational excellence and a thriving team culture. OVERLAND PARK, Kan., July 24, 2025--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR), a fast-growing contract research organization (CRO), is proud to announce the official opening of its new 5,000-square-foot administration building, located on its flagship research campus in Overland Park, Kansas. The expansion marks a major milestone in DVCR's ongoing investment in its people, infrastructure and the future of early phase clinical research. "DVCR first opened its doors in late 2022, and in less than three years, we have grown to approximately 250 employees globally. That growth—combined with being awarded over 100 clinical trials across Phases I through IV—is a true testament to the dedication of our team and the trust our clients place in us," said Dr. Brad Vince, CEO and Chief Medical Officer at DVCR. The new building, which will be celebrated with an employee open house, will be home to DVCR's finance, human resources, marketing and volunteer recruitment teams. Strategically located on the existing 75,000-square-foot campus, the building mirrors the headquarters' architectural style to ensure a seamless and unified environment for employees and visitors alike. "As we continue to attract new biopharmaceutical clients as well as talented clinical researchers, scaling our campus appropriately is essential," said Dr. Vince. "This new facility supports the operational base needed to sustain our momentum and underscores our long-term commitment to the clinical research industry." The project received unanimous approval from the Overland Park Planning Commission in March 2024 and broke ground in June 2025. Completion of the new building comes in under a year, underscoring DVCR's efficient execution and momentum as a CRO leader. About Dr. Vince Clinical Research Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas such as neuroscience, substance abuse, pain, cardiometabolic disorders, infectious diseases and many others. CRO services include project management, data management, biostatistics, statistical programming, PK/PD analysis, medical writing, clinical and medical monitoring as well as site feasibility and management for multi-site trials with our global network of site partners. Additionally, DVCR operates one of the most innovative and technologically advanced clinical pharmacology units in the world with over 90 beds for overnight confinement, a cGMP compliant pharmacy as well as luxurious amenities to support diverse study participant recruitment and retention. By leveraging technology and one of the country's most experienced leadership teams in early clinical development, DVCR provides Smarter Faster Data® to its biopharmaceutical clients. For more information, visit: Connect with DVCR on LinkedIn and YouTube View source version on Contacts Media Contact: Laura HardingVice President, MarketingDr. Vince Clinical Research913-333-3000lharding@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Supio Announces Supio Summit in NYC Featuring Moneyball's Billy Beane as Keynote Speaker
Supio Announces Supio Summit in NYC Featuring Moneyball's Billy Beane as Keynote Speaker

Business Wire

time26 minutes ago

  • Business Wire

Supio Announces Supio Summit in NYC Featuring Moneyball's Billy Beane as Keynote Speaker

SEATTLE--(BUSINESS WIRE)--Supio, the AI-powered legal intelligence platform for personal injury lawyers, today announced Supio Summit, a flagship event bringing together leaders in personal injury law, firm operators, and legal technologists for a half-day of programming, networking, and innovation. The event will take place at Thomson Reuters headquarters in New York City on Thursday, Sept. 18, from 1:00 to 6:00 PM. Headlining the event is Jerry Zhou, CEO and co-founder of Supio, who will share a new vision for how AI will transform plaintiff law as well as key product announcements. He will be joined by Supio product executives and customers, including Nasser Abujbarah from Phillips Law Group. Closing the event is keynote speaker Billy Beane, the former Oakland Athletics executive and subject of 'Moneyball,' whose data-driven approach changed how professional baseball evaluates talent. Beane will share lessons on strategy, disruption and high-impact decision-making from his 'Moneyball' playbook. In a highly competitive market, with well-funded defense firms, plaintiff firms today face a choice: stick with legacy processes or find smarter ways to win using the resources they already have. Beane's keynote will address the decision of how to rethink value, uncover leverage in overlooked places and compete without needing more headcount or bigger budgets. Event Highlights Opening Keynote: Rise of the AI-Driven Firm: A Playbook for Plaintiff Lawyers Speakers: Jerry Zhou, Supio leadership, and Nasser Abujbarah, Managing Attorney, Phillips Law Group. Tech Leaders Panel: AI & Law: Where Are We Now and Where Are We Headed? Moderated by Melia Russell (Business Insider); additional panelists to be announced. Customer Panel: How AI Is Revolutionizing Case Assessment and Litigation Strategy Featuring Supio clients Bill Biggs (Garces Grabler & LeBrocq), Devan Byrd (The Byrd Law Firm), Eric Chaffin (Chaffin Luhana), and Jay Stefani (Levinson + Stefani). Live Demo Stations: Attendees can explore Supio's platform throughout the event with hands-on product walk-throughs and use-case stations, including discovery and case preparation. Registration is now open to personal injury attorneys, litigation staff, law firm leaders, and strategic partners. This event is free, but space is limited. Register at About Supio: Supio is a leading AI platform transforming how personal injury and mass tort law firms build stronger cases and achieve superior outcomes. Supio's Document Intelligence™ Platform converts complex case materials into actionable insights, combining specialized AI with human expert verification to ensure unmatched accuracy. Built with security and compliance at its foundation, Supio streamlines the entire case lifecycle – from pre-litigation analysis to courtroom strategy. Law firms using Supio report faster case resolution, higher settlement values, and deeper client trust through our precision-driven document analysis, advanced case economics, and intelligent drafting tools. About Billy Beane: With trademark wit and sharp business acumen, Billy Beane brings a unique perspective on leadership, innovation, and data-driven transformation. As the Executive Vice President of Baseball Operations and now Senior Adviser to the Oakland A's, Beane implemented a revolutionary analytics-based model that turned one of MLB's lowest payroll teams into a perennial contender – earning 7 AL West titles, 10 playoff appearances, and global recognition through the bestselling book and Oscar-nominated film Moneyball. A four-time MLB Executive of the Year and one of Forbes' '100 Greatest Living Business Minds,' Beane now speaks to organizations across industries – from law and finance to healthcare – on how to find undervalued assets, challenge legacy systems, and build lasting competitive advantage.

Castine Unveils Transformative RMS Upgrade, Redefining Research Management for Asset Managers
Castine Unveils Transformative RMS Upgrade, Redefining Research Management for Asset Managers

Business Wire

time26 minutes ago

  • Business Wire

Castine Unveils Transformative RMS Upgrade, Redefining Research Management for Asset Managers

RIDGEWOOD, N.J.--(BUSINESS WIRE)--Castine unveiled a major upgrade to its Research Management System, introducing reimagined functionality and the addition of over 100 million financial instrument data elements to its library. 'We're creating a living, breathing ecosystem where every datapoint contributes to a broader intelligence network,' said Robin Hodgkins Share The current RMS system is used globally by asset managers to organize, tag, and extract value from both internally generated research as well as content received from hundreds of brokers and research providers. The system became part of Castine's offering following its recent acquisition of Paris-based ResearchPool. The RMS enhancements include an expanded central repository with full integration into Microsoft Office, enabling users to tag and catalog documents at the point of creation, significantly boosting the efficiency and accuracy of repository-wide searches. Personalized Intelligence at Scale Perhaps most revolutionary is the RMS's ability to reflect each user's unique research methodology, business rules and relationship network. Instead of requiring professionals to conform to rigid software structures, the RMS now adapts to their individual workflows, serving as a digital extension of their analytical process. The platform's newly introduced fund holdings views and interactive corporate hierarchy diagrams deliver unprecedented transparency into complex financial structures. Users can now seamlessly visualize end-to-end parent-subsidiary connections with intuitive clarity that reshapes the investment decision-making process. 'We're moved beyond simply managing research, we're creating a living, breathing ecosystem where every datapoint contributes to a broader intelligence network,' said Robin Hodgkins, President of Castine Consulting LLC. 'With these new capabilities, and our expanded data library, Castine RMS is now positioned as the 'command center' for next-generation research operations.' The development and rollout of the upgraded RMS were a collaborative effort across teams in France, Portugal, and Argentina. 'This has been a true team achievement, showcasing the strengths of our long-standing group and the expanded capabilities we now offer as part of the Castine family,' said Castine Director Pedro Fernandes, former President of ResearchPool who led the design and architecture of the RMS suite. The enhanced platform will be available to clients beginning September 1st. About Castine Castine is a global leader in commission management and research solutions, with over 30 years of experience supporting CSA and research programs. Castine serves more than 500 asset managers and brokers and 2000+ research provider. Offices in the United Kingdom, Europe, Argentina, and the United States.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store